34 Initial dosing regimen of Byetta is 5 g subcutaneously twice daily and after one month, the dose is increased to 10 g twice daily based on clinical response (Table 1)
The hypothesis is biologically plausible and provides a rational basis for investigating whether restoring GHK-Cu concentrations, topically or systemically, could support tissue repair
Helping patients ensure that their medications are correctly prescribed, prepared, and available from their insurance provider is essential for long-term success
BPC-157 remains investigational by comparison, with animal data suggesting potential but no controlled human trials confirming cardiovascular benefits
Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development
High-dose supplements of vitamins C and E, low-dose multivitamins, and the risk of age-related cataract: a population-based prospective cohort study of men